These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 37364935)

  • 21. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
    Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ
    J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8
    You G; Lee Y; Kang YW; Park HW; Park K; Kim H; Kim YM; Kim S; Kim JH; Moon D; Chung H; Son W; Jung UJ; Park E; Lee S; Son YG; Eom J; Won J; Park Y; Jung J; Lee SW
    Sci Adv; 2021 Jan; 7(3):. PubMed ID: 33523913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy.
    Liang J; Zhang H; Huang Y; Fan L; Li F; Li M; Yan Y; Zhang J; Li Z; Yang X
    Cancer Manag Res; 2021; 13():6977-6987. PubMed ID: 34522140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
    Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
    Front Immunol; 2022; 13():885424. PubMed ID: 35837391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
    Cao W; Xing H; Li Y; Tian W; Song Y; Jiang Z; Yu J
    Biomark Res; 2022 May; 10(1):38. PubMed ID: 35642043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striking the Balance with a PD-L1×4-1BB Bispecific Antibody.
    Ha J; Grippin AJ; Kim BYS; Jiang W
    Cancer Res; 2024 May; 84(10):1546-1547. PubMed ID: 38745496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer.
    Wang Y; Wang H; Shi T; Song X; Zhang X; Zhang Y; Wang X; Che K; Luo Y; Yu L; Liu B; Wei J
    EMBO Mol Med; 2024 Sep; 16(9):2170-2187. PubMed ID: 39164472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
    Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
    Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
    Compte M; Harwood SL; Erce-Llamazares A; Tapia-Galisteo A; Romero E; Ferrer I; Garrido-Martin EM; Enguita AB; Ochoa MC; Blanco B; Oteo M; Merino N; Nehme-Álvarez D; Hangiu O; Domínguez-Alonso C; Zonca M; Ramírez-Fernández A; Blanco FJ; Morcillo MA; Muñoz IG; Melero I; Rodriguez-Peralto JL; Paz-Ares L; Sanz L; Alvarez-Vallina L
    Clin Cancer Res; 2021 Jun; 27(11):3167-3177. PubMed ID: 33785484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice.
    Sabel MS; Conway TF; Chen FA; Bankert RB
    J Immunother; 2000; 23(3):362-8. PubMed ID: 10838665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
    Ma Z; Zhou Z; Duan W; Yao G; Sheng S; Zong S; Zhang X; Li C; Liu Y; Ou F; Dahar MR; Huang Y; Yu L
    Cancer Immunol Immunother; 2024 Mar; 73(5):82. PubMed ID: 38554200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
    Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
    BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
    Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
    Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation.
    Chiu D; Tavaré R; Haber L; Aina OH; Vazzana K; Ram P; Danton M; Finney J; Jalal S; Krueger P; Giurleo JT; Ma D; Smith E; Thurston G; Kirshner JR; Crawford A
    Cancer Immunol Res; 2020 May; 8(5):596-608. PubMed ID: 32184296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
    Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
    O'Brien NA; McDermott MSJ; Zhang J; Gong KW; Lu M; Hoffstrom B; Luo T; Ayala R; Chau K; Liang M; Madrid AM; Donahue TR; Glaspy JA; Presta L; Slamon DJ
    Mol Cancer Ther; 2023 Dec; 22(12):1365-1375. PubMed ID: 37788341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors.
    Belmontes B; Sawant DV; Zhong W; Tan H; Kaul A; Aeffner F; O'Brien SA; Chun M; Noubade R; Eng J; Ma H; Muenz M; Li P; Alba BM; Thomas M; Cook K; Wang X; DeVoss J; Egen JG; Nolan-Stevaux O
    Sci Transl Med; 2021 Aug; 13(608):. PubMed ID: 34433637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
    Kubota Y; Shitara K
    Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The PET-Tracer
    Griessinger CM; Olafsen T; Mascioni A; Jiang ZK; Zamilpa C; Jia F; Torgov M; Romero JM; Marchioni F; Satpayev D; Lee C; Zhang G; Nayak TK; Pincha M; Amann M; Mohan PLB; Richard M; Nicolini VG; Sam J; Claus C; Ferrara C; Brünker P; Bacac M; Umana P; Rüttinger D; Wilson IA; Gudas J; Klein C; Tessier JJL
    Cancer Res; 2020 Jul; 80(13):2903-2913. PubMed ID: 32409308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.